Impact of Humanistic Care on Healthcare Providers and Patient Outcomes with Dr. Kathy Reeves Arnold P. Gold Foundation
Release Date: 04/24/2024
Deploying Technology in Decentralized Clinical Trials Improves Recruitment and Retention with Alice Lin Tigermed Consulting TRANSCRIPT
Empowered Patient Podcast
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize...
info_outline
Deploying Technology in Decentralized Clinical Trials Improves Recruitment and Retention with Alice Lin Tigermed Consulting
Empowered Patient Podcast
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize...
info_outline
Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our...
info_outline
Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics
Empowered Patient Podcast
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our...
info_outline
Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT TRANSCRIPT
Empowered Patient Podcast
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any...
info_outline
Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT
Empowered Patient Podcast
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any...
info_outline
Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPT
Empowered Patient Podcast
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form...
info_outline
Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates
Empowered Patient Podcast
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form...
info_outline
Preventative and Acute Treatment for Rare Genetic Disease HAE with Salome Juethner Takeda TRANSCRIPT
Empowered Patient Podcast
Salome Juethner, Senior Medical Director, Head of Rare Genetics, and Interim Head of Rare GI at Takeda, discusses HAE, hereditary angioedema, a rare genetic disorder that causes painful and unpredictable swelling attacks that can be life-threatening. Salome emphasizes the need to educate physicians to consider HAE as a potential diagnosis in children as young as two years old and underrepresented racial and ethnic groups. To treat HAE, Takeda offers Takhzyro, a medication that can be used on-demand and as a preventative therapy, administered at home through a subcutaneous injection. ...
info_outline
Preventative and Acute Treatment for Rare Genetic Disease HAE with Salome Juethner Takeda
Empowered Patient Podcast
Salome Juethner, Senior Medical Director, Head of Rare Genetics, and Interim Head of Rare GI at Takeda, discusses HAE, hereditary angioedema, a rare genetic disorder that causes painful and unpredictable swelling attacks that can be life-threatening. Salome emphasizes the need to educate physicians to consider HAE as a potential diagnosis in children as young as two years old and underrepresented racial and ethnic groups. To treat HAE, Takeda offers Takhzyro, a medication that can be used on-demand and as a preventative therapy, administered at home through a subcutaneous injection. ...
info_outlineDr. Kathy Reeves, President and CEO of the Arnold P. Gold Foundation, works with medical schools to promote humanistic care and is responsible for the White Coat ceremony for medical students to emphasize the need for human connection in healthcare. The Foundation is also responsible for the Thank a Resident Day and the Gold Foundation Honor Society, which recognize those doctors who meet the high standards of their peers. The development of Gold Human-Centered Spaces is a scalable solution to create healthcare environments that foster humanistic interactions. The goal is to make humanism a healthcare priority and to implement practical solutions.
Kathy explains, "With that, Arnold and Sandra knew there had to be a foundation dedicated to making sure the human connection remained central in healthcare. And that's what the Gold Foundation has done and continues to do. We are the group that is responsible for the White Coat ceremony when people enter medical school to make sure medical students are aware that it's all about the person in front of them. There are a number of other programs that we do with medical schools, and we're attached to over 90% of the medical schools across the country. We work directly with these schools to help keep healthcare human."
"There is an abundance of research out there that will show you when a patient feels well cared for, they're healthier. When the interaction goes well, the healthcare professional is healthier. Those two things alone lead to lower healthcare costs, less no-show rates, less health professional turnover. So it is in some ways the epitome of value-based care, if we really value people, it's going to save money. It's going to make the society healthier."
#GoldFoundation #Humanism #Healthcare #PatientCentered #EmpowerTeams #ThankAResidentDay
